Abcam plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABCM research report →
About the company
Abcam plc operates as a prominent life science enterprise, dedicated to the innovation, creation, and supply of crucial reagents and instruments. These fundamental resources are instrumental in supporting diverse scientific investigations, diagnostic applications, and the advancement of pharmaceutical drug discovery initiatives. Its comprehensive product portfolio features primary and secondary antibodies, conjugated antibodies paired with their respective kits, both singleplex and multiplex immunoassays, as well as a variety of proteins and peptides, including cytokines.
- CEO
- Alan Thomas Hirzel BS,
- IPO
- 2020
- Employees
- 1,760
- HQ
- Cambridge, GB
Price Chart
- Market Cap
- $5.52B
- P/E
- 578.45
- P/S
- 0.00
- P/B
- 3.88
- EV/EBITDA
- 2.84
- Div Yield
- 0.00%
- Gross Margin
- 71.21%
- Op Margin
- 2.03%
- Net Margin
- 1.40%
- ROE
- 0.76%
- ROIC
- 0.65%
- Revenue
- $361.70M · -23.36%
- Net Income
- $-8,500,000 · -148.47%
- EPS
- $-0.04 · -147.57%
- Op Income
- $53.80M
- FCF YoY
- -144.37%
- 52W High
- $25.32
- 52W Low
- $12.48
- 50D MA
- $23.15
- 200D MA
- $19.98
- Beta
- 0.86
- Avg Volume
- 5.82M
Get TickerSpark's AI analysis on ABCM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ABCM coverage
Recent articles, reports, and earnings notes.
No research on ABCM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABCM report →Similar companies
Peers in the same neighborhood.